- ￥720 - 4560
- MedChemExpress(MCE)
- 美国
- HY-13034
- 2025年12月05日
企业认证
相关产品推荐更多 >
万千商家帮你免费找货
0 人在求购买到急需产品
- 详细信息
- 文献和实验
- 技术资料
- 保存条件：
Powder: -20°C, 3 years; 4°C, 2 years.In solvent: -80°C, 6 months; -20°C, 1 month.
- 英文名：
LY2784544
- 库存：
货期：1-2天
- 供应商：
MedChemExpress LLC
- CAS号：
1229236-86-5
- 规格：
10 mM * 1 mL/5 mg/10 mg/50 mg
| 规格： | 10 mM * 1 mL | 产品价格： | ￥792.0 |
|---|---|---|---|
| 规格： | 5 mg | 产品价格： | ￥720.0 |
| 规格： | 10 mg | 产品价格： | ￥1200.0 |
| 规格： | 50 mg | 产品价格： | ￥4560.0 |
MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务。
Gandotinib
CAS No. : 1229236-86-5
MCE 国际站：Gandotinib
产品活性：Gandotinib (LY2784544) 是一种有效的 JAK2 抑制剂，IC50 为 3 nM。Gandotinib (LY2784544) 也抑制FLT3，FLT4，FGFR2，TYK2 和 TRKB，IC50 分别为 4，25，32，44 和 95 nM。
研究领域：Epigenetics | Protein Tyrosine Kinase/RTK | JAK/STAT Signaling | Stem Cell/Wnt
作用靶点：JAK | FLT3 | FGFR | VEGFR
In Vitro: Gandotinib (LY2784544), a potent, selective and ATP-competitive inhibitor of janus kinase 2 (JAK2) tyrosine kinase. LY2784544 effectively inhibits JAK2V617F-driven signaling and cell proliferation in Ba/F3 cells (IC50=20 and 55 nM, respectively). In comparison, Gandotinib (LY2784544) is much less potent at inhibiting interleukin-3-stimulated wild-type JAK2-mediated signaling and cell proliferation (IC50=1183 and 1309 nM, respectively). Gandotinib (LY2784544) potently inhibits the JAK2V617F signaling (IC50=20 nM) but, remarkably, shows very minimal activity against the IL-3-activated wild-type JAK2 signaling with an IC50 of 1183 nM. LY2784544 inhibits the proliferation of JAK2V617F-expressing cells (IC50=55 nM) and is markedly less potent as an inhibitor of the proliferation of IL-3-stimulated wild-type JAK2 expressing Ba/F3 cells (IC50=1309 nM). Gandotinib (LY2784544) is potent in the cell-based TF-1 JAK2 assay (IC50=45 nM) and had the desired threshold selectivity in the NK-92 JAK3/JAK1 heterodimer assay (942 nM).
In Vivo: Gandotinib (LY2784544) effectively inhibits STAT5 phosphorylation in Ba/F3-JAK2V617F-GFP (green fluorescent protein) ascitic tumor cells (TED50=12.7 mg/kg) and significantly reduces (P<0.05) Ba/F3-JAK2V617F-GFP tumor burden in the JAK2V617F-induced MPN model (TED50=13.7 mg/kg, twice daily).
相关产品：Drug Repurposing Compound Library Plus | Clinical Compound Library Plus | Bioactive Compound Library Plus | Epigenetics Compound Library | Immunology/Inflammation Compound Library | JAK/STAT Compound Library | Kinase Inhibitor Library | Protein Tyrosine Kinase Compound Library | Stem Cell Signaling Compound Library | Anti-Cancer Compound Library | Clinical Compound Library | Anti-Aging Compound Library | Drug Repurposing Compound Library | Differentiation Inducing Compound Library | Reprogramming Compound Library | Anti-COVID-19 Compound Library | Chemical Probe Library | Anti-Breast Cancer Compound Library | Anti-Lung Cancer Compound Library | Anti-Pancreatic Cancer Compound Library | Anti-Blood Cancer Compound Library | Anti-Obesity Compound Library | Angiogenesis-Related Compound Library | Anti-Liver Cancer Compound Library | Anti-Colorectal Cancer Compound Library | Anti-Prostate Cancer Compound Library | Anti-Pulmonary Fibrosis Compound Library | Cancer Stem Cells Compound Library | Pain-Related Compound Library | Membrane Protein-targeted Compound Library | Membrane Receptor-targeted Compound Library | Autoimmune Disease Compound Library | Highly Selective Inhibitors Library | Cytokine Inhibitors Library | Sorafenib | Ruxolitinib | Lenvatinib | Tofacitinib | Sunitinib | Regorafenib | Nintedanib | Bevacizumab | Semaxinib | Cabozantinib | Deucravacitinib | Baricitinib | AG490 | Gilteritinib | Upadacitinib | Ponatinib | Erdafitinib | Fedratinib | Infigratinib | Axitinib | Midostaurin | Quizartinib | Pemigatinib | Chloramphenicol | Pazopanib | Futibatinib | Fexagratinib | PD173074
热门产品线：重组蛋白 | 化合物库 | 天然产物 | 荧光染料 | PROTAC | 同位素标记物
Trending products：Recombinant Proteins | Bioactive Screening Libraries | Natural Products | Dye Reagents | PROTAC | Isotope-Labeled Compounds
风险提示：丁香通仅作为第三方平台，为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全，合理判断，谨慎选购商品，商家和用户对交易行为负责。对于医疗器械类产品，请先查证核实企业经营资质和医疗器械产品注册证情况。
文献和实验ALP U/L 86.27±20.38 276 64.07-106.57
基1%乙烯基(94%)二甲基聚硅氧烷，商品名：OV-5，DB-5，SE-54，HP-5，RTX-5，BP-5 注：2、3常无严格区分，通常混称。 三、中等极性 4、50%Phenyl dimethyl polysiloxane, 50%二苯基(50%)二甲基聚硅氧烷，商品名：OV-17，HP-50，RTX-50 5、14%Cyanopropyl phenyl polysiloxane, 14%氰丙基苯基(其中7%氰丙基7%苯基)(86%)二甲基聚硅氧烷，商品名：AC10，OV-1701，DB
-5，DB-5，SE-54，HP-5，RTX-5，BP-5注：2、3常无严格区分，通常混称。 三、中等极性 4、50%Phenyl dimethyl polysiloxane, 50%二苯基(50%)二甲基聚硅氧烷，商品名：OV-17，HP-50，RTX-50 5、14%Cyanopropyl phenyl polysiloxane, 14%氰丙基苯基(其中7%氰丙基7%苯基)(86%)二甲基聚硅氧烷，商品名：AC10，OV-1701，DB-1701，RTX-1701 6、50
技术资料暂无技术资料 索取技术资料
